Core Insights - The IPO journey of Wuhan Binhui Biotechnology Co., Ltd. is seen as a critical test for the clinical value of oncolytic virus therapies in China, transitioning from a "research concept" to "clinical value" [2] - Binhui Biotechnology has a differentiated advantage with its HSV-2 oncolytic virus candidate BS001, which is the first of its kind to enter Phase III clinical trials globally [2][3] - The global oncolytic virus market is projected to reach $7.5 billion by 2030, but Binhui faces challenges such as ongoing losses, commercialization capabilities, and increasing industry competition [2] Company Overview - Founded in 2010, Binhui Biotechnology focuses on innovative cancer immunotherapy, with a pipeline that includes oncolytic viruses, nucleic acid therapies, and protein biologics [3] - The company is led by Liu Binlei, a core member of the first FDA-approved oncolytic virus drug development team, and has developed BS001, which is currently in Phase III trials for melanoma and other indications [4] Clinical Development - BS001 is undergoing simultaneous Phase III trials in China, the U.S., and Europe, with overall survival as the primary endpoint [4] - The company also has another significant asset, BS006, which targets difficult-to-treat solid tumors and has received clinical approval in China [4] Financial Performance - Binhui has raised over 1.5 billion RMB through 13 rounds of financing, with a valuation of 3.22 billion RMB post-2023 financing [5] - The company reported revenues of 981,000 RMB in 2023, with projections of 1.73 million RMB in 2024, but a significant drop to 140,000 RMB in the first half of 2025 [5][6] - The net loss for 2023 was 110.1 million RMB, increasing to 113.1 million RMB in 2024, with cumulative losses exceeding 270 million RMB over two and a half years [6][7] Cash Flow and Funding - As of June 30, 2025, Binhui held 166 million RMB in cash, while facing a net loss of 113.1 million RMB for 2024, indicating a potential cash flow crisis [7] - The funds raised from the IPO are intended for global Phase III trials of BS001, pipeline development, and commercialization capacity building [8] Commercialization Challenges - Binhui acknowledges limited experience in drug commercialization, which poses a risk to revenue realization [9] - The company faces challenges in building a sales network and educating the market about oncolytic virus therapies, which require specialized knowledge [9][10] - The competitive landscape includes established players like Beijing Anuo Biopharmaceuticals, which has a significant market share and a mature commercialization team [10]

Core Insights - Wuhan's innovative pharmaceutical companies are gaining attention in the capital market, with Wuhan Heyuan Bio (688765.SH) starting its subscription on October 14, and another company, Wuhan Binhui Biotechnology Co., Ltd., seeking a listing on the Hong Kong Stock Exchange [1][2] Company Overview - Binhui Bio, established in November 2010, focuses on oncolytic virus therapy and aims to discover, develop, and commercialize innovative cancer immunotherapies [2][3] - The company has undergone seven rounds of investment, totaling approximately 1.04 billion RMB, with a post-investment valuation of about 3.22 billion RMB as of December 2023 [4] Leadership and Experience - The largest shareholder group, led by Dr. Liu Binlei, holds 26.32% of the company. Dr. Liu has extensive experience in drug research and development, having been a core member of the team that developed the first FDA-approved oncolytic virus drug, IMLYGIC [5][6][7] Product Pipeline - Binhui Bio has established a differentiated pipeline focusing on three strategic series: oncolytic viruses, nucleic acid therapies, and protein biologics, with oncolytic viruses as the core [7][14] - The core product, BS001, is in Phase III clinical trials and has shown an objective response rate of 34.48% in advanced melanoma patients [15][19] Market Potential - The global oncolytic virus market is projected to reach approximately $7.5 billion by 2030, with the Chinese market expected to reach 9.2 billion RMB, driven by increasing clinical applications and investment [12][27] Financial Performance - Binhui Bio has not yet commercialized any products, reporting revenues of 981,000 RMB in 2023 and a cumulative loss of 267 million RMB over two and a half years [22][23] - The company had cash and cash equivalents of approximately 166 million RMB as of June 2025, indicating sufficient operational funding for the next 12 months [25][26]

Core Viewpoint - The article discusses a novel approach to control postoperative tumor recurrence using a stable hydrogel system that releases oncolytic viruses, demonstrating its effectiveness in activating immune responses and preventing tumor regrowth after surgery [3][6]. Group 1: Research Background - Tumors pose a significant threat to human health, and postoperative recurrence is a major challenge for patients who have undergone surgery [2]. - Current treatments like chemotherapy and radiotherapy often have severe side effects, highlighting the need for safer and more effective alternatives [2]. Group 2: Study Findings - The research published in Cell Reports Medicine introduces a hydrogel system (adv@Nap gel) that can continuously release oncolytic viruses post-surgery, effectively controlling tumor recurrence [3][6]. - The study confirms that this hydrogel can activate the type I interferon pathway, inducing both innate and adaptive immunity, thereby controlling postoperative tumor recurrence and extending survival in mice [6]. Group 3: Innovations and Implications - **Local Sustained Release System**: The hydrogel provides continuous release of oncolytic viruses, extending the local immune activation window and aligning with the long-term immune regulation needs post-surgery [7]. - **Synergistic Immune Mechanism**: Oncolytic viruses not only directly lyse tumor cells but also activate immune pathways, transforming "cold tumors" into "hot tumors," enhancing sensitivity to other treatments [7]. - **Multi-Virus Platform Applicability**: The study demonstrates that adenoviruses, herpesviruses, and vaccinia viruses can all be effectively delivered using this hydrogel system, indicating broad applicability across various oncolytic virus types [8]. - **Clinical Translation Potential**: The immediate application of this strategy during surgery addresses both micro-residual disease and immune suppression, offering a low-toxicity, high-efficacy combined treatment approach to reduce tumor recurrence [9].

Core Viewpoint - Binhui Biotech has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International, CMB International, and Bank of China International as joint sponsors [1] Company Overview - Binhui Biotech is a biotechnology company focused on the discovery, development, and commercialization of cancer immunotherapy, specifically on oncolytic virus therapy [1] - The company's lead product, BS001 (OH2 injection), is an oncolytic virus candidate based on type II herpes simplex virus (HSV-2) that selectively replicates in tumor cells and activates systemic immunity [1] Product Development - BS001 is the first oncolytic virus candidate based on HSV-2 to reach clinical stage and enter Phase III pivotal trials globally, currently undergoing a Phase III clinical trial for melanoma in China [1] - BS001 has received orphan drug designation from the FDA for the treatment of stage III-IV melanoma and malignant glioma, as well as fast track designation for treating refractory or progressive melanoma [1] - In a Phase Ia/Ib trial, BS001 demonstrated a median overall survival of 31.06 months, with an objective response rate of 34.48%, and up to 42.1% in patients resistant to PD-1 therapy [1] Leadership and Expertise - The company is led by Dr. Liu Binlei, who has over 30 years of experience in tumor immunology and oncolytic virology, and was a core member of the development team for the FDA-approved oncolytic virus drug IMLYGIC® (T-VEC) [1]

Core Viewpoint - Wuhang Binhui Biotechnology Co., Ltd. has submitted its main board listing application, focusing on oncolytic virus therapy, with a valuation of 3.22 billion yuan after financing in 2023, despite continuous losses exceeding 270 million yuan from 2023 to the first half of 2025 [1][3]. Group 1: Company Overview - Binhui Biotechnology, established in 2010, specializes in the discovery, development, and commercialization of innovative cancer immunotherapy, particularly oncolytic virus therapy [2]. - The core product, BS001 (OH2 injection), is the first HSV-2 oncolytic virus candidate to reach Phase III clinical trials globally, designed to selectively replicate in tumor cells and activate systemic immune responses [2]. Group 2: Financial Data - The company is currently in the "concept phase," with no approved products for commercial sale, resulting in negligible revenue: 980,000 yuan in 2023, 1.725 million yuan in 2024, and only 140,000 yuan in the first half of 2025, a 44% year-on-year decline [3]. - Net losses have been increasing: 110 million yuan in 2023, 113 million yuan in 2024, and 44.22 million yuan in the first half of 2025, with adjusted losses reaching 39.21 million yuan [3][4]. Group 3: Challenges and Risks - The company acknowledges limited experience in drug commercialization, which may hinder its ability to establish a sales network and generate market recognition, impacting revenue generation [6]. - The production, cold chain transport, and administration of oncolytic virus drugs require high-quality control, and the company currently lacks a dedicated sales team, with fewer than 200 employees [6]. - Regulatory scrutiny is increasing for genetically modified viral agents, and any safety signals during Phase III trials could delay market approval, leading to a potential scenario of "no products, no revenue" if BS001 fails to gain approval [6].

Core Viewpoint - Wuhan Binhui Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange and has advanced its core product BS001 to Phase III clinical trials for treating melanoma, showcasing its innovative approach in oncolytic virus therapy [1][2]. Company Overview - Binhui Biotechnology is a biotech company focused on the discovery, development, and commercialization of innovative cancer immunotherapies, particularly oncolytic virus therapies [1]. - The company is led by Dr. Liu Binlei, who has over 30 years of expertise in tumor immunology and oncolytic virology, and was a key member of the original development team for the FDA-approved oncolytic virus drug IMLYGIC [1]. Product Pipeline - The company has established a diverse pipeline with five products at various stages of development, including BS001, which is a novel oncolytic virus candidate based on HSV-2 [2]. - BS001 is designed to selectively replicate within tumor cells, induce oncolytic effects, and activate systemic immune responses by secreting hGM-CSF [2]. - The product is being studied as a monotherapy and in combination with other therapies, particularly PD-1 inhibitors, for various solid tumor indications, including melanoma, colorectal cancer, glioblastoma, soft tissue sarcoma, and biliary cancer [2]. Clinical Development - BS001 is the first oncolytic virus candidate based on HSV-2 to reach clinical stage and enter Phase III trials globally, with the potential to be the first approved HSV-2 based oncolytic virus therapy [3]. - It has received breakthrough therapy designation from the drug evaluation center and orphan drug status from the FDA for treating advanced melanoma and glioblastoma [3]. - The ongoing Phase III trial for melanoma uses overall survival as the primary endpoint, with previous trials showing a median overall survival of 31.06 months and an objective response rate of 34.48% in advanced melanoma patients [3]. Financial Performance - For the fiscal years 2023 and 2024, the company reported revenues of RMB 0.981 million and RMB 1.725 million, respectively, while incurring losses of approximately RMB 110 million and RMB 113 million [4]. - The financial results for the six months ending June 30, 2024, and 2025, showed revenues of RMB 0.25 million and RMB 0.14 million, with losses of RMB 43.748 million and RMB 44.215 million, respectively [4].

Core Viewpoint - Wuhan Binhui Biotechnology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to commercialize innovative cancer immunotherapy through oncolytic virus therapy [1][3]. Company Overview - Binhui Biotechnology is focused on the discovery, development, and commercialization of innovative cancer immunotherapies, specifically oncolytic virus therapies that aim to meet urgent clinical needs globally [3]. - The company is led by Dr. Liu Binlei, who has over 30 years of expertise in tumor immunology and oncolytic virology, and was a core member of the team that developed the first FDA-approved oncolytic virus drug, IMLYGIC [3]. Product Pipeline - Binhui has established a diverse pipeline with five products at various development stages, including the core product BS001, an oncolytic virus candidate based on HSV-2 [4]. - BS001 selectively replicates in tumor cells, triggering oncolysis and activating systemic immune responses, and is being studied for various solid tumor indications, including melanoma and colorectal cancer [4]. Clinical Development - BS001 is the first oncolytic virus candidate based on HSV-2 to reach the clinical stage and enter Phase III trials, with the potential to be the first approved therapy of its kind globally [5]. - The drug has received breakthrough therapy designation and orphan drug status from the FDA for treating advanced melanoma and glioblastoma, and has shown promising early clinical trial results [5]. Financial Performance - For the fiscal years ending June 30, 2023, and 2024, Binhui reported revenues of 0.981 million and 1.725 million RMB, respectively, with significant losses of approximately 110.1 million and 113.1 million RMB [6][7]. - The company has incurred substantial research and development expenses, amounting to 106.8 million RMB in 2023, reflecting its focus on advancing its clinical programs [7].

香港交易及結算所有限公司、香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不 負責，對其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Binhui Biopharmaceutical Co., Ltd. 武 漢 濱 會 生 物 科 技 股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求而刊 發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知 悉、接納並向本公司、本公司的聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，本公司不會 向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香 港公司註冊處處長註冊的本公司招股章程作出投資決定，招股章程的 ...

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Binhui Biopharmaceutical Co., Ltd. 武 漢 濱 會 生 物 科 技 股 份 有 限 公 司 (the ''Com ...

Core Viewpoint - Jimin Health (603222.SH) is transitioning from a focus on large-volume infusion, medical devices, and healthcare services to becoming an innovative pharmaceutical company, marked by the acceptance of a clinical trial application for DB006 on September 26, 2025 [1]. Group 1: Company Transition - Jimin Health's subsidiary, Boao International Hospital, received a clinical trial acceptance notice for DB006, a oncolytic adenovirus injection, indicating the company's first step towards becoming an innovative drug enterprise [1]. - The registration classification of DB006 is as a Class 1 therapeutic biological product, signifying a significant shift in Jimin Health's business model since its establishment in 1996 [1]. Group 2: Market Context - In 2020, China reported 4.57 million new cancer cases and 3 million cancer deaths, with high incidence and mortality rates for liver, stomach, esophageal, and cervical cancers [1]. - Breast cancer has the highest incidence rate, followed by lung and colorectal cancers, with lung cancer remaining the leading cause of cancer-related deaths [1]. Group 3: Oncolytic Virus Therapy - Oncolytic virus therapy is recognized as a promising new type of cancer treatment, characterized by high efficiency in killing tumor cells, specificity, safety, low side effects, and cost-effectiveness [2]. - Currently, five oncolytic virus drugs have been approved globally, with approximately seven oncolytic virus drugs in clinical trials in China, most in Phase I/II [2]. Group 4: Product Details - DB006 is designed for the treatment of advanced malignant solid tumors, utilizing genetic engineering to enhance tumor-specific replication and selectively infect tumor cells [2]. - In preclinical models, DB006 demonstrated over 70% tumor suppression in colon cancer models and complete tumor remission in non-small cell lung cancer models [2]. Group 5: Financial Performance - In the first half of 2025, Jimin Health reported total revenue of 366 million yuan, a decrease of 21.3% year-on-year, with a net loss attributable to shareholders of 52.7 million yuan [3]. - The company attributed its losses to reduced revenue and profit from medical devices due to U.S. tariff policies and inventory write-downs related to specific products [3].